Another trial for the TARGET trial. Author's reply

Stefan Hagel^{1

2}, Mathias W Pletz^{3

4}, Thomas Lehmann⁵

Affiliations

¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany. stefan.hagel@med.uni-jena.de.
² Center for Sepsis Control and Care (CSCC), Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany. stefan.hagel@med.uni-jena.de.
³ Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
⁴ Center for Sepsis Control and Care (CSCC), Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
⁵ Institute of Medical Statistics, Computer Sciences and Data Sciences, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.

Comment

Stefan Hagel et al. Intensive Care Med. 2022 Jun.

. 2022 Jun;48(6):776-777.

doi: 10.1007/s00134-022-06670-9. Epub 2022 Mar 23.

Stefan Hagel^{1

2}, Mathias W Pletz^{3

4}, Thomas Lehmann⁵

¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany. stefan.hagel@med.uni-jena.de.
² Center for Sepsis Control and Care (CSCC), Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany. stefan.hagel@med.uni-jena.de.
³ Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
⁴ Center for Sepsis Control and Care (CSCC), Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
⁵ Institute of Medical Statistics, Computer Sciences and Data Sciences, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.

No abstract available

Conflict of interest statement

All others do not have any conflicts of interest relevant to the manuscript.

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Intensive Care Med. 2022 Mar;48(3):311-321. doi: 10.1007/s00134-021-06609-6. Epub 2022 Feb 1. Intensive Care Med. 2022. PMID: 35106617 Free PMC article. Clinical Trial.
Another trial for the TARGET trial.
Alshaer MH, Peloquin CA. Alshaer MH, et al. Intensive Care Med. 2022 Jun;48(6):774-775. doi: 10.1007/s00134-022-06654-9. Epub 2022 Mar 1. Intensive Care Med. 2022. PMID: 35230463 No abstract available.

1. Alshaer MH, Peloquin CA. Another trial for the TARGET trial. Intensive Care Med. 2022 doi: 10.1007/s00134-022-06654-9. - DOI - PubMed
1. Hagel S, Bach F, Brenner T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022 doi: 10.1007/s00134-021-06609-6. - DOI - PMC - PubMed